NS1-Truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10293-10301

  Pica, Natalie ^a   Langlois, Ryan A ^a   Krammer, Florian ^a   Margine, Irina ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE; LIVE VACCINE; NS1 126 VIRUS VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION; VIRUS DETECTION; VIRUS REPLICATION;

AGING; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEK293 CELLS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, ATTENUATED; VIRAL NONSTRUCTURAL PROTEINS;

MUS; ORTHOMYXOVIRIDAE;

EID: 84866982674     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01131-12     Document Type: Article

References (78)

1. Asanuma H, et al. 2012. A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 30:803-812.
2. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Samb-hara S. 2007. Challenges for vaccination in the elderly. Immun. Ageing 4:9.
3. Baskin CR, et al. 2007. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J. Virol. 81:11817-11827.
4. Beli E, et al. 2011. Natural killer cell function is altered during the primary response of aged mice to influenza infection. Mech. Ageing Dev. 132:503-510.
5. Bender BS, Johnson MP, Small PA. 1991. Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection. Immunology 72:514-519.
6. Bender BS, et al. 1998. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice. Vaccine 16:1748-1755. 7. Ben-Yehuda A, Ehleiter D, Hu AR, Weksler ME. 1993. Recombinant
7. Ben-Yehuda A, Ehleiter D, Hu AR, Weksler ME. 1993. Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old
8. Bernstein E, et al. 1999. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17:82-94.
9. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. 1998. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16:1722-1731.
10. Beyer WE, Palache AM, de Jong JC, Osterhaus AD. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A metaanalysis. Vaccine 20:1340-1353.
11. Bhushan M, et al. 2002. Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br. J. Dermatol. 146:32-40.
12. Boon AC, et al. 2009. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J. Virol. 83: 10417-10426.
13. Canaday DH, et al. 2010. Influenza-induced production of interferonalpha is defective in geriatric individuals. J. Clin. Immunol. 30:373-383.
14. CDC. 2010. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone High-Dose) and guidance for use- United States, 2010. MMWR Morb. Mortal. Wkly. Rep. 59:485-486.
15. Couch RB, et al. 2007. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25:7656-7663.
16. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
17. Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. 2009. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 31:491-501.
18. Donelan NR, Basler CF, Garcia-Sastre A. 2003. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 77:13257-13266.
19. Donelan NR, et al. 2004. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J. Virol. 78:11574-11582.
20. Durbin JE, et al. 2000. Type I IFN modulates innate and specific antiviral immunity. J. Immunol. 164:4220-4228.
21. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. 2004. Agerelated defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J. Exp. Med. 200:1613-1622.
22. Effros RB, Walford RL. 1983. The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell. Immunol. 81:298-305.
23. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65years of age and older. J. Infect. Dis. 200:172-180.
24. Ferko B, et al. 2006. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J. Virol. 80:11621-11627.
25. Ferko B, et al. 2004. Immunogenicity and protection efficacy of replication- deficient influenza A viruses with altered NS1 genes. J. Virol. 78: 13037-13045.
26. GarcíA-Sastre A, et al. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330.
27. Goodwin K, Viboud C, Simonsen L. 2006. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24:1159-1169.
28. Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. 2004. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J. Virol. 78:7610-7618.
29. Hai R, et al. 2008. Influenza B virus NS1-truncated mutants: liveattenuated vaccine approach. J. Virol. 82:10580-10590.
30. Haynes L, Swain SL. 2006. Why aging T cells fail: implications for vaccination. Immunity 24:663-666.
31. Hobbs FB. 2008. 8 July 2008, posting date. The elderly population. http://www.census.gov/prod/1/pop/p23-190/p23-190.pdf.
32. Jiang J, et al. 2009. Limited expansion of virus-specific CD8 T cells in the aged environment. Mech. Ageing Dev. 130:713-721.
33. Jiang J, Fisher EM, Murasko DM. 2011. CD8 T cell responses to influenza virus infection in aged mice. Ageing Res. Rev. 10:422-427.
34. Johnson PR, Feldman S, Thompson JM, Mahoney JD, Wright PF. 1986. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J. Infect. Dis. 154:121-127.
35. Katz JM, Lu X, Todd CW, Newman MJ. 2000. A nonionic block copolymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. Vaccine 18:2177-2187.
36. Keitel WA, et al. 2006. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166:1121-1127.
37. Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J. 1996. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc. Natl. Acad. Sci. U. S. A. 93:3043-3047.
38. Le Bon A, et al. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14:461-470.
39. Le Bon A, et al. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176:2074-2078.
40. Leng J, et al. 2011. Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 29:8147-8155.
41. Listì F, et al. 2006. A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann. N. Y. Acad. Sci. 1089:487-495.
42. Louie JK, et al. 2011. A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California. PLoS One 6:e18221. doi:10.1371/ journal.pone.0018221.
43. Lowen AC, et al. 2009. Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J. Virol. 83:2803-2818.
44. Lustig A, et al. 2009. Transcriptome analysis of murine thymocytes reveals age-associated changes in thymic gene expression. Int. J. Med. Sci. 6:51-64.
45. Lynch JP, III, Walsh EE. 2007. Influenza: evolving strategies in treatment and prevention. Semin. Respir. Crit. Care Med. 28:144-158.
46. Mariani E, et al. 2002. Chemokine production by natural killer cells from nonagenarians. Eur. J. Immunol. 32:1524-1529.
47. Mariani E, et al. 2002. RANTES and MIP-1alpha production by T lymphocytes, monocytes and NK cells from nonagenarian subjects. Exp. Gerontol. 37:219-226.
48. Matrosovich M, Matrosovich T, Garten W, Klenk HD. 2006. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3:63.
49. Mbawuike IN, Wyde PR, Anderson PM. 1990. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 8:347-352.
50. Mueller SN, Langley WA, Carnero E, Garcia-Sastre A, Ahmed R. 2010. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J. Virol. 84:1847-1855.
51. Panda A, et al. 2009. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 30:325-333.
52. Pica N, et al. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. U. S. A. 109:2573-2578.
53. Pica N, et al. 2011. The DBA. 2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses. J. Virol. 85:12825-12829.
54. Plowden J, et al. 2004. Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol. 229:86-92.
55. Powers DC, Belshe RB. 1993. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J. Infect. Dis. 167:584-592.
56. Quinlivan M, et al. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79:8431-8439.
57. Riedl K, Riedl R, von Gabain A, Nagy E, Lingnau K. 2008. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice. Vaccine 26:3461-3468.
58. Romanova J, et al. 2009. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS One 4:e5984. doi: 10.1371/journal.pone.0005984.
59. Sambhara S, et al. 1998. Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Vaccine 16:1698-1704.
60. Schneider-Ohrum K, et al. 2011. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 29:9081-9092.
61. Sheahan T, et al. 2011. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J. Virol. 85:217-230.
62. Solórzano A, et al. 2005. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 79:7535-7543.
63. Speziali E, et al. 2009. Specific immune responses but not basal functions of B and T cells are impaired in aged mice. Cell Immunol. 256:1-5.
64. Steel J, et al. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83:1742-1753.
65. Steinman RM, Hemmi H. 2006. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311:17-58.
66. Takeoka Y, et al. 1996. The murine thymic microenvironment: changes with age. Int. Arch. Allergy Immunol. 111:5-12.
67. Talon J, et al. 2000. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. U. S. A. 97:4309-4314.
68. Toapanta FR, Ross TM. 2009. Impaired immune responses in the lungs of aged mice following influenza infection. Respir. Res. 10:112.
69. Valkenburg SA, et al. 2012. Early priming minimizes the age-related immune compromise of CD8(+) T cell diversity and function. PLoS Pathog. 8:e1002544. doi:10.1371/journal.ppat.1002544.
70. Vincent AL, et al. 2007. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25:7999-8009.
71. Wacheck V, et al. 2010. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J. Infect. Dis. 201:354-362.
72. Wang L, et al. 2008. Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine 26:3580-3586.
73. Wang TT, Palese P. 2009. Unraveling the mystery of swine influenza virus. Cell 137:983-985.
74. Wen Z, et al. 2009. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res. 84: 215-224.
75. Yager EJ, et al. 2008. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med. 205:711-723.
76. Zhou B, et al. 2010. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 28:8015-8025